Clinical Trials Logo

Clinical Trial Summary

The purpose of this post-marketing surveillance is to investigate and confirm the type and incidence of newly identified adverse events and any other factors affecting safety and efficacy of Sprycel® so that the regulatory authority can manage the marketing approval properly.


Clinical Trial Description

n/a


Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT01464047
Study type Observational
Source Bristol-Myers Squibb
Contact
Status Completed
Phase N/A
Start date October 2011
Completion date August 2015

See also
  Status Clinical Trial Phase
Terminated NCT02841540 - A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes Phase 1
Completed NCT02807272 - Tipifarnib in Subjects With Chronic Myelomonocytic Leukemia, Other MDS/MPN, and Acute Myeloid Leukemia Phase 2
Terminated NCT01957644 - Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients With MDS or CMML Phase 1
Active, not recruiting NCT03268954 - Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) Phase 3
Completed NCT00255346 - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) Phase 2
Withdrawn NCT04264806 - A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) Phase 2
Completed NCT02472691 - Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT Phase 2
Terminated NCT00109538 - Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED) Phase 3
Completed NCT00025662 - Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS Phase 2
Completed NCT02891551 - An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands
Terminated NCT00510289 - Sorafenib in Myelodysplastic Syndrome Phase 2
Completed NCT03814005 - A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems Phase 1
Completed NCT00744536 - Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS Phase 2
Completed NCT02907359 - Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Phase 3
Completed NCT01519011 - Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine Phase 1
Completed NCT05218902 - A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Terminated NCT03175978 - IGF-MTX Conjugate in the Treatment of Myelodysplastic Syndrome Phase 1/Phase 2
Recruiting NCT03040401 - A Study of HDC/IL-2 Treatment in Chronic Myelomonocytic Leukemia (CMML) Phase 1/Phase 2
Recruiting NCT05201066 - Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab. Phase 2
Active, not recruiting NCT05883956 - A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia Phase 3